雌激素受体β与大鼠骨髓基质干细胞成脂肪分化相关性研究

目的:通过对大鼠骨髓基质干细胞成脂肪分化过程中雌激素受体β表达规律的研究,进一步明确雌激素受体β与骨代谢的相关性。方法:大鼠骨髓基质干细胞培养,成骨诱导分化,钙染色。成脂肪诱导分化,油红O染色。Western blot方法测定大鼠骨髓基质干细胞成脂肪分化过程中雌激素受体β的表达。结果:全骨髓贴壁方法培养获得大鼠骨髓基质干细胞。成脂诱导分化显微镜下脂肪滴、油红O染色阳性细胞随成脂肪时间增加而增多。雌激素受体β的表达随成脂时间的增加而递增。结论:大鼠骨髓基质干细胞成脂肪分化过程中ERβ的表达随时间逐渐增加。     

医疗机构中药制剂创新和持续发展能力评价研究

目的 对医疗机构中药制剂创新和持续发展能力进行综合评价,为行政管理部门决策及各医院中药制剂可持续发展提供参考。方法 以浙江省133家医疗机构中药制剂调研数据为对象,利用层次分析法构建医疗机构中药制剂创新和持续发展能力评价体系,通过反向传播神经网络构建中药制剂室/中心评价体系预测模型。结果 构建的医疗机构中药制剂创新和持续发展能力评价指标体系包含4项二级指标以及19项三级指标,其中研发品种数、超百万品种数、注册品种数、研发方式、制剂室面积指标的权重值较高,分别为 0.15758、0.12928、0.09343、0.07879和0.07458。熵权法结合层次分析法的指标权重构建反向传播神经网络,Levenberg-Marquardt算法和Scaled Conjugate Gradient算法训练模型总体相关系数分别为0.98983和0.9348。结论 本研究构建了一个科学有效的医疗机构中药制剂创新和持续发展能力综合评价体系,可实现对医疗机构中药制剂综合能力的预测评价。     

中医药在动脉粥样硬化中的抗炎作用研究

动脉粥样硬化（AS）是一种慢性、进展性、系统性的炎症疾病,是心脑血管疾病的主要病理基础,严重的危害人类健康。“炎症在AS的发生、发展和演变中起重要作用”这一观点已得到广泛的肯定。动脉粥样硬化发病机制中的炎症学说,为中医药的应用提供了理论基础。现将近年来中医药在AS中的抗炎研究情况综述如下。     

卵巢早衰治疗策略探讨

目的　评价性激素替代治疗 (hormonereplacementtreatment,HRT)对卵巢早衰 (prematureovarianfail ure ,POF)患者的疗效 ,探讨卵巢早衰可能有效的促排卵方案。方法　采用前瞻性研究方法对 19例卵巢早衰患者 ,行HRT共 3～ 6个周期 ,观察服药前后临床症状、盆腔超声相、血清生殖激素变化及停药后卵泡发育情况 ,并对个别患者行促排卵治疗观察疗效。结果　 19例患者经HRT临床症状明显缓解。与服药前比较 ,血清卵泡刺激素 (FSH)水平明显下降 (P <0 0 1) ,血清黄体生成素 (LH)水平显著下降 (P <0 0 5 )。双侧卵巢及子宫体积无显著变化 (P >0 0 5 ) ,子宫内膜明显增厚 (P <0 0 1)。停药后 1例自然妊娠 ,1例自发排卵 ,1例用促性腺激素释放激素激动剂 (GnRHa) /绝经期促性腺激素 (HMG) /绒毛膜促性腺激素 (HCG)治疗有排卵。服药期间无肝功能损伤及其它副反应。结论　性激素替代治疗卵巢早衰 3～ 6个周期 ,可使临床症状缓解 ,血清FSH、LH明显下降 ,利于促排卵治疗成功。     

Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission

Background: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to explore the effect of allo-HSCT (especially haploidentical HSCT [haplo-HSCT]) on improving survival and reducing relapse for HR childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in...     

电纺参数对PLGA/HA复合支架纤维形貌和直径的影响

目的通过静电纺丝的方法制备PLGA/HA复合支架,探讨电纺参数对复合支架纤维形貌和直径的影响。方法以三氯甲烷和N,N-二甲基甲酰胺为混合溶剂制备PLGA/HA纺丝液,通过调节PLGA的浓度、电压、接收距离,制备具有不同表面形貌的PLGA/HA复合纤维,采用SEM观察PLGA的浓度、电压、接收距离对纤维形貌和直径的影响。结果复合纤维的直径随PLGA浓度的增加而增加;随电压的增加而增加;随接收距离的增加先减小后增加。结论制备PLGA/HA复合支架较合适的电纺参数为：PLGA浓度25%,电压20KV,接收距离15cm。静电纺丝法制得的PLGA/HA复合支架有可能作为骨组织再生的支架在组织工程领域发挥作用。     

维脑路通片压片工段工艺质量回顾分析

目的：通过维脑路通片压片工段工艺质量回顾分析,保证药品质量的安全生产要求。维脑路通是芦丁经羟乙基化半合成的产物,对抗5-羟色胺、缓激肽引起的血管损伤,增加毛细血管抵抗力,能降低毛细血管的通透性和脆性,并有抑制血小板凝集、防止血栓形成的作用,降低毛细血管通透性,可防止血管通透性升高引起的水肿。对急性缺血性脑损伤有显著的保护作用。适用于脑血栓形成和脑栓塞所致的偏瘫、失语以及心肌梗死前综合征、动脉硬化等。维脑路通是临床上治疗闭塞性脑血管病的常用药物。根据2010年修订的《药品生产质量管理规范》第二百六十六条要求,企业至少应当对关键中间控制点及成品的检验结果进行回顾分析。方法：是通过联系跟踪95批次的产品,进行片重的分析。结果：是平均偏差SD=0.000467,平均数average=0.125679,相对平均偏差RSD=0.003716,RSD（％）=0.3716,RSD<3％,符合方法学要求。结论：是验证工厂使用的压片机的性能符合GMP的要求,达到了阶段性的压片工段的质量管理要求。     

Study on modified shengmai yin injection for prevention and treatment of brain impairment in endotoxin shock rats

Objective:To examine the effects of modified Shenmai Yin on invigorating vital energy, promoting blood flow, and protection against neural impairment in an endotoxin-induced shock rat model. Methods: Ninety-six SD rats were randomly divided into four groups: sham operation (saline 20 ml/kg), shock model (lipopolysaccharide, LPS, 8 mg/kg), Reformed Shengmai Yin (加味生脉饮 Pulse-activating Decoction) (LPS 8 mg/kg + reformed Shengmai Yin Injection 10 ml/kg), and dexamethasone (LPS 8 mg/kg + dexamethasone 5 mg/kg) groups. Each group was subdivided into 1 h, 2 h, 3 h, and 6 h time points for observation. The carotid artery was separated and connected with a biological functional system to monitor mean arterial pressure (MAP). Brain water levels, malonaldehyde (MDA) content, and superoxide dismutase (SOD) activity were also determined. Results: In the shock model group, MAP was progressively decreased after injection of LPS, brain water and MDA contents were increased, brain SOD activity was decreased, and capillary vessel edema in brain tissue was also observed. All these parameters were improved significantly in both treatment groups, although the effects were more marked with Shengmai Yin than with dexamethasone. Conclusion: Modified Shengmai Yin exhibits strong anti-shock and neuroprotective effects against Endotoxininduced shock.     

Rituximab for the treatment of refractory anti-glomerular basement membrane disease

BackgroundAnti-glomerular basement membrane (anti-GBM) disease is a rare but severe autoantibody-mediated immune disorder. The typical clinical presentation includes rapidly progressive glomerulonephritis and often concurrent pulmonary hemorrhage. The present study is aimed to investigate the therapeutic effects of rituximab either used alone or with other immunosuppressants.MethodsEight patients diagnosed with anti-GBM disease and treated with rituximab from 2014 to 2020 were retrospectively reviewed.ResultsEight patients included 5 males and 3 females with a median age of 58.5 years. They all presented severe kidney injuries and 1 patient had lung hemorrhage. At diagnosis, the median of serum creatinine was 246 µmol/L (ranging from 91 to 850 µmol/L), with 3 patients requiring dialysis. All of them received corticosteroids and plasmapheresis. Rituximab was given as either standard four weekly doses or one pulse ranging from 100 to 600 mg. After a median follow-up of 34.5 months, kidney function was partially recovered or stabilized in 5/8 (62.5%) patients, free of dialysis. Anti-GBM antibodies remained undetected in all patients during follow-up. No severe adverse effect associated with rituximab was observed.ConclusionRituximab may be an alternative therapy in the treatment of patient with severe or refractory anti-GBM disease.